Showing results (141-150 of 152) with videos related to
Sort By:
Pageof 16
Scientific Reports|May 8, 2026
Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patientsMuhammet Cengiz, Oktay Bozkurt, Ayse Nuransoy Cengiz, et al.BMC Cancer|December 30, 2024
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studySeda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, et al.Journal of Chemotherapy (Florence, Italy)|September 11, 2024
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaHasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, et al.Frontiers in Immunology|December 26, 2025
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter studyTaha Koray Sahin, Fatih Atalah, Bahadir Koylu, et al.Journal of Chemotherapy (Florence, Italy)|January 24, 2024
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencingOsman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology GroupSalih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu, et al.Journal of Clinical Medicine|February 27, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective AnalysisBaris Koksal, Hasan Cagri Yildirim, Deniz Can Guven, et al.Therapeutic Advances in Medical Oncology|March 16, 2026
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studyTaha Koray Sahin, Fatih Kemik, Harun Muglu, et al.Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudyMustafa Seyyar, Ali Kalem, Mürsel Sali, et al.Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.Pageof 16